Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lili Feng#, Zhenyu Liu#, Chaofeng Li#, Zhenhui Li#, Xiaoying Lou#, Lizhi Shao#, Yunlong Wang, Yan Huang, Haiyang Chen, Xiaolin Pang, Shuai Liu, Fang He, Jian Zheng, Xiaochun Meng, Peiyi Xie, Guanyu Yang, Yi Ding, Mingbiao Wei, Jingping Yun, Mien-Chie Hung, Weihua Zhou, Daniel R Wahl, Ping Lan, Jie Tian* and Xiangbo Wan*. ![]() Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik-Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen-Shi Chen, Li-Yuan Bai, Sung-Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara and Narikazu Boku*.Mechanism regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. ![]() ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |